S&P 500   3,962.25 (-0.38%)
DOW   32,359.58 (-0.22%)
QQQ   305.37 (-1.10%)
AAPL   156.40 (-1.19%)
MSFT   272.83 (-1.28%)
META   199.35 (-1.72%)
GOOGL   100.73 (-1.69%)
AMZN   96.64 (-1.43%)
TSLA   186.96 (-2.53%)
NVDA   261.93 (-1.27%)
NIO   9.14 (+2.35%)
BABA   98.44 (+14.31%)
AMD   93.81 (-2.90%)
T   18.76 (-0.58%)
F   11.55 (+0.26%)
MU   58.69 (-1.84%)
CGC   1.82 (-3.19%)
GE   92.69 (-0.66%)
DIS   94.74 (-0.92%)
AMC   5.20 (+14.29%)
PYPL   72.10 (-1.64%)
PFE   39.86 (-0.90%)
NFLX   323.09 (-1.39%)
S&P 500   3,962.25 (-0.38%)
DOW   32,359.58 (-0.22%)
QQQ   305.37 (-1.10%)
AAPL   156.40 (-1.19%)
MSFT   272.83 (-1.28%)
META   199.35 (-1.72%)
GOOGL   100.73 (-1.69%)
AMZN   96.64 (-1.43%)
TSLA   186.96 (-2.53%)
NVDA   261.93 (-1.27%)
NIO   9.14 (+2.35%)
BABA   98.44 (+14.31%)
AMD   93.81 (-2.90%)
T   18.76 (-0.58%)
F   11.55 (+0.26%)
MU   58.69 (-1.84%)
CGC   1.82 (-3.19%)
GE   92.69 (-0.66%)
DIS   94.74 (-0.92%)
AMC   5.20 (+14.29%)
PYPL   72.10 (-1.64%)
PFE   39.86 (-0.90%)
NFLX   323.09 (-1.39%)
S&P 500   3,962.25 (-0.38%)
DOW   32,359.58 (-0.22%)
QQQ   305.37 (-1.10%)
AAPL   156.40 (-1.19%)
MSFT   272.83 (-1.28%)
META   199.35 (-1.72%)
GOOGL   100.73 (-1.69%)
AMZN   96.64 (-1.43%)
TSLA   186.96 (-2.53%)
NVDA   261.93 (-1.27%)
NIO   9.14 (+2.35%)
BABA   98.44 (+14.31%)
AMD   93.81 (-2.90%)
T   18.76 (-0.58%)
F   11.55 (+0.26%)
MU   58.69 (-1.84%)
CGC   1.82 (-3.19%)
GE   92.69 (-0.66%)
DIS   94.74 (-0.92%)
AMC   5.20 (+14.29%)
PYPL   72.10 (-1.64%)
PFE   39.86 (-0.90%)
NFLX   323.09 (-1.39%)
S&P 500   3,962.25 (-0.38%)
DOW   32,359.58 (-0.22%)
QQQ   305.37 (-1.10%)
AAPL   156.40 (-1.19%)
MSFT   272.83 (-1.28%)
META   199.35 (-1.72%)
GOOGL   100.73 (-1.69%)
AMZN   96.64 (-1.43%)
TSLA   186.96 (-2.53%)
NVDA   261.93 (-1.27%)
NIO   9.14 (+2.35%)
BABA   98.44 (+14.31%)
AMD   93.81 (-2.90%)
T   18.76 (-0.58%)
F   11.55 (+0.26%)
MU   58.69 (-1.84%)
CGC   1.82 (-3.19%)
GE   92.69 (-0.66%)
DIS   94.74 (-0.92%)
AMC   5.20 (+14.29%)
PYPL   72.10 (-1.64%)
PFE   39.86 (-0.90%)
NFLX   323.09 (-1.39%)
NASDAQ:RETA

Reata Pharmaceuticals - RETA Stock Forecast, Price & News

$87.78
-0.75 (-0.85%)
(As of 03/28/2023 02:32 PM ET)
Add
Compare
Today's Range
$86.26
$90.14
50-Day Range
$30.85
$93.17
52-Week Range
$18.47
$95.00
Volume
341,142 shs
Average Volume
1.54 million shs
Market Capitalization
$3.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$95.00

Reata Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
10.0% Upside
$96.89 Price Target
Short Interest
Healthy
18.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.89mentions of Reata Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$9.70 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($8.44) to ($8.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

240th out of 1,002 stocks

Pharmaceutical Preparations Industry

98th out of 488 stocks


RETA stock logo

About Reata Pharmaceuticals (NASDAQ:RETA) Stock

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX.

Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RETA Stock News Headlines

The Stock That Tripled in a Day...And May Not Be Done
Reata Pharmaceuticals now has a long-coveted commercialized drug in its portfolio. Should investors covet this biotech stock for their portfolios?
Where Reata Pharmaceuticals Stands With Analysts
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Reata Pharmaceuticals
Reata Pharmaceuticals (NASDAQ: RETA)
Why Reata Pharmaceuticals Stock Is Soaring Today
Why Is Reata Pharmaceuticals (RETA) Stock Up 15% Today?
See More Headlines
Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RETA Company Calendar

Last Earnings
11/08/2021
Today
3/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RETA
Fax
N/A
Employees
346
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$96.89
High Stock Price Forecast
$138.00
Low Stock Price Forecast
$67.00
Forecasted Upside/Downside
+7.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-311,900,000.00
Net Margins
-9,897.91%
Pretax Margin
-14,076.08%

Debt

Sales & Book Value

Annual Sales
$2.22 million
Book Value
($1.79) per share

Miscellaneous

Free Float
26,186,000
Market Cap
$3.25 billion
Optionable
Optionable
Beta
1.27

Social Links


Key Executives

  • J. Warren Huff
    Chairman & Chief Executive Officer
  • Manmeet Singh Soni
    President, Chief Operating & Financial Officer
  • W. Christian Wigley
    Chief Scientific Officer & Senior Vice President
  • Samina Khan
    Chief Medical Officer & Senior Vice President
  • Dakota Gallivan
    VP, Chief Healthcare & Compliance Officer













RETA Stock - Frequently Asked Questions

Should I buy or sell Reata Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RETA shares.
View RETA analyst ratings
or view top-rated stocks.

What is Reata Pharmaceuticals' stock price forecast for 2023?

6 Wall Street research analysts have issued 1-year price objectives for Reata Pharmaceuticals' stock. Their RETA share price forecasts range from $67.00 to $138.00. On average, they anticipate the company's stock price to reach $96.89 in the next year. This suggests a possible upside of 9.4% from the stock's current price.
View analysts price targets for RETA
or view top-rated stocks among Wall Street analysts.

How have RETA shares performed in 2023?

Reata Pharmaceuticals' stock was trading at $37.99 at the beginning of the year. Since then, RETA shares have increased by 133.0% and is now trading at $88.53.
View the best growth stocks for 2023 here
.

Are investors shorting Reata Pharmaceuticals?

Reata Pharmaceuticals saw a decrease in short interest in March. As of March 15th, there was short interest totaling 5,030,000 shares, a decrease of 39.8% from the February 28th total of 8,360,000 shares. Based on an average daily volume of 1,420,000 shares, the days-to-cover ratio is currently 3.5 days. Approximately 18.1% of the company's shares are short sold.
View Reata Pharmaceuticals' Short Interest
.

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) announced its quarterly earnings data on Monday, November, 8th. The company reported ($1.97) EPS for the quarter, topping analysts' consensus estimates of ($2.32) by $0.35. The business earned $7.40 million during the quarter, compared to analyst estimates of $2.07 million. Reata Pharmaceuticals had a negative trailing twelve-month return on equity of 922.50% and a negative net margin of 9,897.91%. The company's revenue was up 428.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.94) EPS.

What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?

10 employees have rated Reata Pharmaceuticals Chief Executive Officer Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among the company's employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an initial public offering on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO.

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Who are Reata Pharmaceuticals' major shareholders?

Reata Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include First Light Asset Management LLC (5.63%), Fred Alger Management LLC (4.12%), Deutsche Bank AG (4.07%), Boxer Capital LLC (3.36%), Morgan Stanley (2.00%) and Emerald Advisers LLC (1.86%). Insiders that own company stock include Andrea Loewen, Bhaskar Anand, Colin John Meyer, Dawn Carter Bir, Elaine Castellanos, James Warren Huff, Manmeet Singh Soni, Michael D Wortley, Samina Khan and Shamim Ruff.
View institutional ownership trends
.

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $88.53.

How much money does Reata Pharmaceuticals make?

Reata Pharmaceuticals (NASDAQ:RETA) has a market capitalization of $3.25 billion and generates $2.22 million in revenue each year. The company earns $-311,900,000.00 in net income (profit) each year or ($8.56) on an earnings per share basis.

How many employees does Reata Pharmaceuticals have?

The company employs 346 workers across the globe.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The official website for the company is www.reatapharma.com. The company can be reached via phone at (972) 865-2219 or via email at ir@reatapharma.com.

This page (NASDAQ:RETA) was last updated on 3/28/2023 by MarketBeat.com Staff